On the other hand, methylfolate is the biologically-active form of B9 and what the body uses directly

GLP-1 timeline: what to expect month by month Month 1: Getting started Target: 2-3% of your starting weight lost You'll notice reduced hunger and cravings quite quickly Energy may dip slightly as your body adjusts Some people experience mild nausea or digestive changes Month 2: Finding your rhythm Target: 4-5% total weight loss from baseline Hunger control becomes more consistent Side effects typically settle down You might increase to your first stable dose around now Month 3: Building momentum Target: 5-8% total weight loss from baseline Clothes fit differently, even if the scales slow down Energy levels start to improve New habits are beginning to stick Months 4-6: Steady progress Month 6 target: 10-15% total loss Weight loss continues at a steady, sustainable pace You're likely settled into a stable dose that's working well Focus on maintaining muscle through protein and activity Months 6-12: Consolidation Month 12 target: 15-20% total weight loss from baseline Progress may slow but remains consistent Body composition changes become really noticeable Many people reach their target weight or body composition goal Your dose might stay the same for months at a time Beyond 12 months: Maintenance You may stay on medication long-term or transition to a maintenance dose The goal shifts to keeping weight off, not losing indefinitely Regular check-ins help you adjust your approach as needed Some people step down to a lower dose while maintaining their results Which GLP-1 weight loss injections are avaliable

in the case of semaglutide 2.4mg, glucose disorder (prediabetes or DT2), hypertension, dyslipidemia, sleep obstructive apnea, or cardiovascular disease
Along these lines, gastric inhibitory polypeptide (GIP) triggers release of GLP-1 from cell lines resembling L-cells and in animal experiments (rodents) [36]
Orlistat (Xenical/Alli), a lipase inhibitor available on the NHS, typically produces mean weight loss of around 35% compared with placebo over 12 months, making it a modest option for many patients
Nutritional deficits for the infant